Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00126760" target="_blank" >RIV/00216224:14110/22:00126760 - isvavai.cz</a>

Výsledek na webu

<a href="https://programme.cirse2022.cirse.org/cirse2022poster/crs/prognostic-factors-for-survival-in-patients-with-unresectable-cancer-of-biliary-origin-treated-with-percutaneous-transhepatic-drainage" target="_blank" >https://programme.cirse2022.cirse.org/cirse2022poster/crs/prognostic-factors-for-survival-in-patients-with-unresectable-cancer-of-biliary-origin-treated-with-percutaneous-transhepatic-drainage</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00270-022-03246-4" target="_blank" >10.1007/s00270-022-03246-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

Popis výsledku v původním jazyce

Purpose: To identify factors affecting survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage (PTD). Materials and Methods: This single-centre retrospective study included 233 consecutive patients undergoing PTD for cancer of biliary origin at a tertiary referral hospital from 1/2005 to 12/2019. Cox regression model was used to assess variables related to overall survival after initial PTD. The variables included demographic (age, sex), imaging (mass forming vs. infiltrative, size of mass forming tumor, localisation, Bismuth-Corlette classification in hilar tumors, presence of metastasis), laboratory (bilirubin, liver enzymes and inflammatory markers before and 3-7 days after the procedure, and hemoglobin, thrombocytes, urea and creatinine before the procedure), and treatment parameters of PTD (number of percutaneous drains, presence and number of implanted metal stents, and performance of endobiliary radiofrequency ablation). Results: In multivariate analysis, age (HR 1.23 per 10 years, p=0.005), location (gallbladder cancer HR 2.82 and p&lt;0.001 compared to hilar cancer; common bile duct cancer HR 0.64 and p=0.049; papilla Vateri HR 0.31 and p=0.002), size of the mass (HR 1.07 per cm, p=0.005), level of bilirubin (≥250 umol/L with HR 1.57 and p=0.009) and hemoglobin (≤110 g/L with HR 1.93 and p=0.001) were shown to be significant factors affecting survival in patients with cancer of biliary origin since first PTD. Conslusion: Age, tumour location, mass size, bilirubin and hemoglobin levels before the first PTD have been shown to be significant prognostic factors for survival in patients with cancer of biliary origin treated with PTD.

Název v anglickém jazyce

Prognostic factors for survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage

Popis výsledku anglicky

Purpose: To identify factors affecting survival in patients with unresectable cancer of biliary origin treated with percutaneous transhepatic drainage (PTD). Materials and Methods: This single-centre retrospective study included 233 consecutive patients undergoing PTD for cancer of biliary origin at a tertiary referral hospital from 1/2005 to 12/2019. Cox regression model was used to assess variables related to overall survival after initial PTD. The variables included demographic (age, sex), imaging (mass forming vs. infiltrative, size of mass forming tumor, localisation, Bismuth-Corlette classification in hilar tumors, presence of metastasis), laboratory (bilirubin, liver enzymes and inflammatory markers before and 3-7 days after the procedure, and hemoglobin, thrombocytes, urea and creatinine before the procedure), and treatment parameters of PTD (number of percutaneous drains, presence and number of implanted metal stents, and performance of endobiliary radiofrequency ablation). Results: In multivariate analysis, age (HR 1.23 per 10 years, p=0.005), location (gallbladder cancer HR 2.82 and p&lt;0.001 compared to hilar cancer; common bile duct cancer HR 0.64 and p=0.049; papilla Vateri HR 0.31 and p=0.002), size of the mass (HR 1.07 per cm, p=0.005), level of bilirubin (≥250 umol/L with HR 1.57 and p=0.009) and hemoglobin (≤110 g/L with HR 1.93 and p=0.001) were shown to be significant factors affecting survival in patients with cancer of biliary origin since first PTD. Conslusion: Age, tumour location, mass size, bilirubin and hemoglobin levels before the first PTD have been shown to be significant prognostic factors for survival in patients with cancer of biliary origin treated with PTD.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

<a href="/cs/project/NU21-08-00561" target="_blank" >NU21-08-00561: Využití ireverzibilní elektroporace a vysokofrekvenční ireverzibilní elektroporace k léčbě okluzí metalických stentů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů